|
| 37573352 | The NightLife study - the clinical and cost-effectiveness of thrice-weekly, extended, in-centre nocturnal haemodialysis versus daytime haemodialysis using a mixed methods approach: study protocol for a randomised controlled trial. | Trials | 2023 |
| 35339234 | Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial. | Lancet Respir Med | 2022 |
| 35606763 | The effectiveness of the Structured Health Intervention For Truckers (SHIFT): a cluster randomised controlled trial (RCT). | BMC Med | 2022 |
| 35157829 | Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial. | Lancet Oncol | 2022 |
| 33515503 | Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. | Lancet Respir Med | 2021 |
| 32245569 | Intravenous sildenafil citrate and post-cardiac surgery acute kidney injury: a double-blind, randomised, placebo-controlled trial. | Br J Anaesth | 2020 |
| 31785830 | Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial. | Radiother Oncol | 2020 |
| 30364431 | Effect of sildenafil (Revatio) on postcardiac surgery acute kidney injury: a randomised, placebo-controlled clinical trial: the REVAKI-2 trial protocol. | Open Heart | 2018 |
| 30420699 | Pathway-based subnetworks enable cross-disease biomarker discovery. | Nat Commun | 2018 |
| 28649643 | Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine. | NPJ Breast Cancer | 2017 |
| 28494403 | HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. | Eur J Cancer | 2017 |
| 29185098 | Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial. | Ann Surg Oncol | 2017 |
| 26296293 | Addressing overtreatment of screen detected DCIS; the LORIS trial. | Eur J Cancer | 2015 |
| 24212561 | EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. | Bone Marrow Transplant | 2014 |
| 25314051 | Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer. | Br J Cancer | 2014 |
| 25071141 | Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. | J Clin Oncol | 2014 |
| 23223186 | Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. | Leukemia | 2013 |
| 24091623 | Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial. | Br J Cancer | 2013 |
| 23395505 | Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant. | Leuk Res | 2013 |
| 21422407 | Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. | J Clin Oncol | 2011 |
| 19951968 | Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. | Haematologica | 2010 |
| 19344426 | Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. | Br J Haematol | 2009 |